Asthma Clinical Trial
Official title:
The Role of GER in Exercise Triggered Asthma
HYPOTHESIS
Gastroesophageal reflux is a major contributor to exercise-triggered asthma.
Two groups of patients will be studied: those with asthma who have difficulty with exertion,
those without asthma who experience difficulty with exertion. Both groups will experience
gastroesophageal reflux (GER) twice of less per week. Patients will complete a treadmill
exam to determine their VO2 max. They will then undergo pH monitoring while exercising for
30 minutes at 65-70% of their VO2 max. Subjects will be given placebo or acid suppression
pill for 12 weeks. At the end of 12 weeks, the subjects will repeat the exercise (30
minutes) and 24-hour pH study.
PRIMARY OBJECTIVE
To determine whether patients with exercise-triggered asthma experience GER during exercise.
SECONDARY OBJECTIVES
To determine whether the exercise-induced GER within the subjects relates temporally to
their exertional asthma.
To evaluate the efficacy of potent acid suppression with a proton pump inhibitor in
suppressing exercise-triggered GER and asthma in these subjects.
METHODS
Population to be evaluated:
Exercise-triggered asthmatics – defined as asthmatics with exertion as their primary
exacerbating factor and experiencing less than two episodes of classic gastroesophageal
reflux a week.
These patients will be randomized into three different treatment groups:
1. Placebo BID
2. 20 mg Aciphex QD and placebo QPM
3. 20 mg Aciphex BID
12 patients will be studied in each group.
DATA
pH data - Data will be collected on the frequency and duration of the reflux episodes
(number of episodes and the percent time the esophageal pH is less than 4.0). This will then
be correlated with the respiratory symptom and changes in spirometry. A symptom index will
be designed to associate the episodes of reflux and bronchospasm that occur within 5 minutes
of a drop in esophageal pH.
Exercise Tolerance/Symptoms - comparisons will be made between the three groups regarding
symptomatology during exercise after randomization to either placebo or differing doses of
Aciphex.
Spirometry testing – done after exercise test. Comparisons between baseline and following
treatment Symptoms scores – both the overall numerical grades of the patients quality of
life and the number of asthmatic episodes and rescue inhaler use will be compared to
baseline after the 12 week study.
STUDY DURATION
The asthma database at the University covers approximately 500 patients. A database search
will be performed to identify patients suitable for recruitment. Additional recruitment, if
needed, will be pursued through radio advertising. Once the study is initiated, the baseline
time for therapy is 12 weeks for each patient. An estimate of the time necessary to complete
the study is 15 months.
STATISTICS
Exercise triggered asthma has not been well studied with respect to its relationship to GER.
This study will be considered a pilot study with 12 subjects per arm. Results from this
study may be used to power a follow up study.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|